Pfizer says its new COVID pill cuts risk of hospitalization, death by nearly 90%

The New York-based drugmaker announced it would no longer be taking on new patients for a clinical trial of the antiviral treatment "due to the overwhelming efficacy," and that it planned to submit its findings to the Food and Drug Administration as well as international health regulators as soon as possible.